FAB
vs
F
FTSE All Share Index
FAB
Over the past 12 months, FAB has significantly outperformed FTSE All Share Index, delivering a return of +77% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
FAB vs FTSE All Share Index
Performance Gap
FAB vs FTSE All Share Index
Performance By Year
FAB vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
